Skip to main content
Top
Published in: Radiation Oncology 1/2014

Open Access 01-12-2014 | Research

Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma

Authors: Khinh Ranh Voong, Kelli McSpadden, Chelsea C Pinnix, Ferial Shihadeh, Valerie Reed, Mohammad R Salehpour, Isidora Arzu, He Wang, David Hodgson, John Garcia, Michalis Aristophanous, Bouthaina S Dabaja

Published in: Radiation Oncology | Issue 1/2014

Login to get access

Abstract

Purpose

High cure rates for Hodgkin’s lymphoma must be balanced with long-term treatment-related toxicity. Here we report an intensity-modulated radiation therapy (IMRT) technique that achieves adequate target coverage for mediastinal disease while minimizing high- and low-dose exposure of critical organs.

Methods and materials

Treatment plans for IMRT and conventional anteroposterior-posteroanterior (AP-PA) techniques, with comparable coverage of the planning target volume (PTV), were generated for 9 female patients with mediastinal Hodgkin’s lymphoma assuming use of inclined positioning, daily breath-hold, and CT-on-rails verification. Our “butterfly” IMRT beam arrangement involved anterior beams of 300°−30° and posterior beams of 160°−210°. Percentages of normal structures receiving 30 Gy (V30), 20 Gy (V20), and 5 Gy (V5) were tabulated for the right and left breasts, total lung, heart, left and right ventricles, left anterior descending coronary artery (LAD), and spinal cord. Differences in each variable, conformity index, homogeneity index, and V107% between the two techniques were calculated (IMRT minus conventional).

Results

Use of IMRT generally reduced the V30 and V20 to critical structures: −1.4% and +0.1% to the right breast, −1.7% and −0.9% to the left breast, −14.6% and −7.7% to the total lung, −12.2% and −10.5% to the heart, −2.4% and −14.2% to the left ventricle, −16.4% and −8.4% to the right ventricle, −7.0% and −14.2% to the LAD, and −52.2% and −13.4% to the spinal cord. Differences in V5 were +6.2% for right breast, +2.8% for left breast, +12.9% for total lung, −3.5% for heart, −8.2% for left ventricle, −1.5% for right ventricle, +0.1% for LAD, and −0.1% for spinal cord. Use of IMRT significantly reduced the volume of tissue receiving 107% of the dose (mean 754 cm3 reduction).

Conclusions

This butterfly technique for IMRT avoids excess exposure of heart, breast, lung, and spinal cord to doses of 30 or 20 Gy; mildly increases V5 to the breasts; and decreases the V107%.
Appendix
Available only for authorised users
Literature
1.
go back to reference Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V: Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010, 363: 640-652.CrossRefPubMed Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V: Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010, 363: 640-652.CrossRefPubMed
2.
go back to reference Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin’s Lymphoma Study G: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003, 21: 3601-3608.CrossRefPubMed Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin’s Lymphoma Study G: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003, 21: 3601-3608.CrossRefPubMed
3.
go back to reference Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79: 270-277.CrossRefPubMed Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79: 270-277.CrossRefPubMed
4.
go back to reference Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004, 22: 2835-2841.CrossRefPubMed Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004, 22: 2835-2841.CrossRefPubMed
5.
go back to reference Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Peny AM, Girinsky T, Raemaekers JM, Henry-Amar M: Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol 2006, 24: 3128-3135.CrossRefPubMed Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Peny AM, Girinsky T, Raemaekers JM, Henry-Amar M: Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol 2006, 24: 3128-3135.CrossRefPubMed
6.
go back to reference Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290: 465-475.CrossRefPubMed Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290: 465-475.CrossRefPubMed
7.
go back to reference van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van’t Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 2003, 95: 971-980.CrossRefPubMed van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van’t Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 2003, 95: 971-980.CrossRefPubMed
8.
go back to reference Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, Whitton JA, Diller L, Kenney L, Donaldson SS, Meadows AT, Neglia JP: Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27: 3901-3907.PubMedCentralCrossRefPubMed Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, Whitton JA, Diller L, Kenney L, Donaldson SS, Meadows AT, Neglia JP: Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27: 3901-3907.PubMedCentralCrossRefPubMed
9.
go back to reference Dabaja BS, Rebueno NC, Mazloom A, Thorne S, Perrin KJ, Tolani N, Das P, Delclos ME, Iyengar P, Reed VK, Horace P, Salehpour MR: Radiation for Hodgkin’s lymphoma in young female patients: a new technique to avoid the breasts and decrease the dose to the heart. Int J Radiat Oncol Biol Phys 2011, 79: 503-507.CrossRefPubMed Dabaja BS, Rebueno NC, Mazloom A, Thorne S, Perrin KJ, Tolani N, Das P, Delclos ME, Iyengar P, Reed VK, Horace P, Salehpour MR: Radiation for Hodgkin’s lymphoma in young female patients: a new technique to avoid the breasts and decrease the dose to the heart. Int J Radiat Oncol Biol Phys 2011, 79: 503-507.CrossRefPubMed
10.
go back to reference Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ: Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011, 79: 10-18.PubMedCentralCrossRefPubMed Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ: Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011, 79: 10-18.PubMedCentralCrossRefPubMed
12.
go back to reference Feuvret L, Noel G, Mazeron JJ, Bey P: Conformity index: a review. Int J Radiat Oncol Biol Phys 2006, 64: 333-342.CrossRefPubMed Feuvret L, Noel G, Mazeron JJ, Bey P: Conformity index: a review. Int J Radiat Oncol Biol Phys 2006, 64: 333-342.CrossRefPubMed
13.
go back to reference Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, Xu T, Huang L, Sachs RK, Brenner DJ: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110: 2576-2586.CrossRefPubMed Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, Xu T, Huang L, Sachs RK, Brenner DJ: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110: 2576-2586.CrossRefPubMed
14.
go back to reference De Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE: Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27: 4239-4246.CrossRefPubMed De Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE: Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27: 4239-4246.CrossRefPubMed
15.
go back to reference Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, Hodgson DC: A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2: 13.PubMedCentralCrossRefPubMed Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, Hodgson DC: A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2: 13.PubMedCentralCrossRefPubMed
16.
go back to reference Sachs RK, Shuryak I, Brenner D, Fakir H, Hlatky L, Hahnfeldt P: Second cancers after fractionated radiotherapy: stochastic population dynamics effects. J Theor Biol 2007, 249: 518-531.PubMedCentralCrossRefPubMed Sachs RK, Shuryak I, Brenner D, Fakir H, Hlatky L, Hahnfeldt P: Second cancers after fractionated radiotherapy: stochastic population dynamics effects. J Theor Biol 2007, 249: 518-531.PubMedCentralCrossRefPubMed
17.
go back to reference Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N: Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008, 72: 24-33.PubMedCentralCrossRefPubMed Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N: Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008, 72: 24-33.PubMedCentralCrossRefPubMed
18.
go back to reference Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR: Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81: 490-497.CrossRefPubMed Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR: Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81: 490-497.CrossRefPubMed
19.
go back to reference Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca VC, Ragona R, Tofani S, Ricardi U: Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7: 186.PubMedCentralCrossRefPubMed Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca VC, Ragona R, Tofani S, Ricardi U: Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7: 186.PubMedCentralCrossRefPubMed
Metadata
Title
Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma
Authors
Khinh Ranh Voong
Kelli McSpadden
Chelsea C Pinnix
Ferial Shihadeh
Valerie Reed
Mohammad R Salehpour
Isidora Arzu
He Wang
David Hodgson
John Garcia
Michalis Aristophanous
Bouthaina S Dabaja
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-9-94

Other articles of this Issue 1/2014

Radiation Oncology 1/2014 Go to the issue